Literature DB >> 18855126

Prevalence and characteristics of pancreatic cancer in families with BRCA1 and BRCA2 mutations.

Daniel H Kim1, Beth Crawford, John Ziegler, Mary S Beattie.   

Abstract

A growing body of research describes cancers other than breast and ovarian in families with BRCA1/2 mutations, but the prevalence and characteristics of pancreatic cancer in these families has not been well described. This study was designed to: (1) estimate the prevalence of pancreatic cancer in BRCA1/2 positive families; (2) ascertain age of onset and gender distribution of pancreatic cancer in this cohort; and (3) compare age and gender characteristics of pancreatic cancer in BRCA1/2 positive families with those of the general population. Within the UCSF Cancer Risk Program cohort, 24/219 (11.0%) BRCA1 and 17/156 (10.9%) BRCA2 families had at least 1 individual with pancreatic cancer. In the 24 BRCA1 families, median age of diagnosis was 59 (range 45-80) in males, and 68 (range 38-87) in females (male:female ratio = 2.00). In the 17 BRCA2 families, median age of diagnosis was 67 (range 39-78) in males and 59 (range 46-81) in females (male:female ratio = 1.11). The SEER database, which describes cancer characteristics in a representative sample of the US population, reports a median age of 70 in males and 74 in females (male:female ratio = 0.96) over the same time period. Additionally, mean ages of diagnosis of pancreatic cancer in BRCA1/2 families differ significantly from the SEER mean (P = 0.0014 for BRCA1 and P = 0.011 for BRCA2 by unpaired t-test). Our findings suggest that families with early onset pancreatic cancer and features of hereditary breast and ovarian cancer should be considered for BRCA1/2 testing.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18855126      PMCID: PMC2683202          DOI: 10.1007/s10689-008-9220-x

Source DB:  PubMed          Journal:  Fam Cancer        ISSN: 1389-9600            Impact factor:   2.375


  23 in total

Review 1.  Frequency of recurrent BRCA1 and BRCA2 mutations in Ashkenazi Jewish breast cancer families.

Authors:  P Tonin; B Weber; K Offit; F Couch; T R Rebbeck; S Neuhausen; A K Godwin; M Daly; J Wagner-Costalos; D Berman; G Grana; E Fox; M F Kane; R D Kolodner; M Krainer; D A Haber; J P Struewing; E Warner; B Rosen; C Lerman; B Peshkin; L Norton; O Serova; W D Foulkes; J E Garber
Journal:  Nat Med       Date:  1996-11       Impact factor: 53.440

2.  Germline BRCA2 gene mutations in patients with apparently sporadic pancreatic carcinomas.

Authors:  M Goggins; M Schutte; J Lu; C A Moskaluk; C L Weinstein; G M Petersen; C J Yeo; C E Jackson; H T Lynch; R H Hruban; S E Kern
Journal:  Cancer Res       Date:  1996-12-01       Impact factor: 12.701

3.  Environmental and heritable factors in the causation of cancer--analyses of cohorts of twins from Sweden, Denmark, and Finland.

Authors:  P Lichtenstein; N V Holm; P K Verkasalo; A Iliadou; J Kaprio; M Koskenvuo; E Pukkala; A Skytthe; K Hemminki
Journal:  N Engl J Med       Date:  2000-07-13       Impact factor: 91.245

4.  Cancer Incidence in BRCA1 mutation carriers.

Authors:  Deborah Thompson; Douglas F Easton
Journal:  J Natl Cancer Inst       Date:  2002-09-18       Impact factor: 13.506

Review 5.  Effectiveness of preventive interventions in BRCA1/2 gene mutation carriers: a systematic review.

Authors:  M J Bermejo-Pérez; S Márquez-Calderón; A Llanos-Méndez
Journal:  Int J Cancer       Date:  2007-07-15       Impact factor: 7.396

6.  Shared genetic susceptibility to breast cancer, brain tumors, and Fanconi anemia.

Authors:  Kenneth Offit; Orna Levran; Brian Mullaney; Katherine Mah; Khedoudja Nafa; Sat Dev Batish; Raffaella Diotti; Hildegard Schneider; Amie Deffenbaugh; Thomas Scholl; Virginia K Proud; Mark Robson; Larry Norton; Nathan Ellis; Helmut Hanenberg; Arleen D Auerbach
Journal:  J Natl Cancer Inst       Date:  2003-10-15       Impact factor: 13.506

7.  Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2.

Authors:  Mary-Claire King; Joan H Marks; Jessica B Mandell
Journal:  Science       Date:  2003-10-24       Impact factor: 47.728

Review 8.  Cancer risks for male carriers of germline mutations in BRCA1 or BRCA2: a review of the literature.

Authors:  Alexander Liede; Beth Y Karlan; Steven A Narod
Journal:  J Clin Oncol       Date:  2004-02-15       Impact factor: 44.544

9.  Are BRCA1- and BRCA2-related breast cancers associated with increased mortality?

Authors:  D Gareth Evans; Anthony Howell
Journal:  Breast Cancer Res       Date:  2004       Impact factor: 6.466

10.  A combined analysis of outcome following breast cancer: differences in survival based on BRCA1/BRCA2 mutation status and administration of adjuvant treatment.

Authors:  Mark E Robson; Pierre O Chappuis; Jaya Satagopan; Nora Wong; Jeff Boyd; John R Goffin; Clifford Hudis; David Roberge; Larry Norton; Louis R Bégin; Kenneth Offit; William D Foulkes
Journal:  Breast Cancer Res       Date:  2003-10-24       Impact factor: 6.466

View more
  10 in total

1.  Uterine serous carcinoma: increased familial risk for lynch-associated malignancies.

Authors:  Summer B Dewdney; Nora T Kizer; Abegail A Andaya; Sheri A Babb; Jingqin Luo; David G Mutch; Amy P Schmidt; Louise A Brinton; Russell R Broaddus; Nilsa C Ramirez; Phyllis C Huettner; Donald Scott McMeekin; Kathleen Darcy; Shamshad Ali; Patricia L Judson; Robert S Mannel; Shashikant B Lele; David M O'Malley; Paul J Goodfellow
Journal:  Cancer Prev Res (Phila)       Date:  2012-01-13

Review 2.  Pancreatic ductal adenocarcinoma: risk factors, screening, and early detection.

Authors:  Andrew E Becker; Yasmin G Hernandez; Harold Frucht; Aimee L Lucas
Journal:  World J Gastroenterol       Date:  2014-08-28       Impact factor: 5.742

3.  Prevalence of Homologous Recombination-Related Gene Mutations Across Multiple Cancer Types.

Authors:  Arielle L Heeke; Michael J Pishvaian; Filipa Lynce; Joanne Xiu; Jonathan R Brody; Wang-Juh Chen; Tabari M Baker; John L Marshall; Claudine Isaacs
Journal:  JCO Precis Oncol       Date:  2018-07-23

Review 4.  The genetics of ductal adenocarcinoma of the pancreas in the year 2020: dramatic progress, but far to go.

Authors:  Elizabeth D Thompson; Nicholas J Roberts; Laura D Wood; James R Eshleman; Michael G Goggins; Scott E Kern; Alison P Klein; Ralph H Hruban
Journal:  Mod Pathol       Date:  2020-07-23       Impact factor: 7.842

5.  Pancreatic cancer as a sentinel for hereditary cancer predisposition.

Authors:  Erin L Young; Bryony A Thompson; Deborah W Neklason; Matthew A Firpo; Theresa Werner; Russell Bell; Justin Berger; Alison Fraser; Amanda Gammon; Cathryn Koptiuch; Wendy K Kohlmann; Leigh Neumayer; David E Goldgar; Sean J Mulvihill; Lisa A Cannon-Albright; Sean V Tavtigian
Journal:  BMC Cancer       Date:  2018-06-27       Impact factor: 4.430

6.  Prevalence of pancreaticobiliary cancers in Irish families with pathogenic BRCA1 and BRCA2 variants.

Authors:  Robert Power; Cristin Leavy; Carmel Nolan; Niamh White; Roisin Clarke; Karen A Cadoo; David James Gallagher; Maeve Aine Lowery
Journal:  Fam Cancer       Date:  2020-09-12       Impact factor: 2.375

Review 7.  BRCA-mutant pancreatic ductal adenocarcinoma.

Authors:  Eleonora Lai; Pina Ziranu; Dario Spanu; Marco Dubois; Andrea Pretta; Simona Tolu; Silvia Camera; Nicole Liscia; Stefano Mariani; Mara Persano; Marco Migliari; Clelia Donisi; Laura Demurtas; Valeria Pusceddu; Marco Puzzoni; Mario Scartozzi
Journal:  Br J Cancer       Date:  2021-07-14       Impact factor: 9.075

8.  The role of BRCA1 and BRCA2 mutations in prostate, pancreatic and stomach cancers.

Authors:  Helen Cavanagh; Katherine M A Rogers
Journal:  Hered Cancer Clin Pract       Date:  2015-08-01       Impact factor: 2.857

9.  BRCA1 and Oxidative Stress.

Authors:  Yong Weon Yi; Hyo Jin Kang; Insoo Bae
Journal:  Cancers (Basel)       Date:  2014-04-03       Impact factor: 6.639

10.  Frequency and Significance of Abnormal Pancreatic Imaging in Patients with BRCA1 and BRCA2 Genetic Mutations.

Authors:  Elie Chahla; Antonio Cheesman; Suzanne M Mahon; Robert W Garrett; Ben P Bradenham; Theresa L Schwartz; Louay Omran; Jason R Taylor; Samer Alkaade
Journal:  Scientifica (Cairo)       Date:  2016-03-16
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.